The DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.
Matching chelators to radiometals for radiopharmaceuticals
Abstract
Radiometals comprise many useful radioactive isotopes of various metallic elements. When properly harnessed, these have valuable emission properties that can be used for diagnostic imaging techniques, such as single photon emission computed tomography (SPECT, e.g.(67)Ga, (99m)Tc, (111)In, (177)Lu) and positron emission tomography (PET, e.g.(68)Ga, (64)Cu, (44)Sc, (86)Y, (89)Zr), as well as therapeutic applications (e.g.(47)Sc, (114m)In, (177)Lu, (90)Y, (212/213)Bi, (212)Pb, (225)Ac, (186/188)Re). A fundamental critical component of a radiometal-based radiopharmaceutical is the chelator, the ligand system that binds the radiometal ion in a tight stable coordination complex so that it can be properly directed to a desirable molecular target in vivo. This article is a guide for selecting the optimal match between chelator and radiometal for use in these systems. The article briefly introduces a selection of relevant and high impact radiometals, and their potential utility to the fields of radiochemistry, nuclear medicine, and molecular imaging. A description of radiometal-based radiopharmaceuticals is provided, and several key design considerations are discussed. The experimental methods by which chelators are assessed for their suitability with a variety of radiometal ions is explained, and a large selection of the most common and most promising chelators are evaluated and discussed for their potential use with a variety of radiometals. Comprehensive tables have been assembled to provide a convenient and accessible overview of the field of radiometal chelating agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shannon, R. D. (1976) · Acta Crystallographica Section A · doi:10.1107/s0567739476001551 · Cited by 66,145
Critical Stability Constants: First Supplement
Martell, A. E., & Smith, R. M. (1982) · Springer eBooks · doi:10.1007/978-1-4615-6761-5 · Cited by 6,008
Firestone, R. B., & Shirley, V. S. (1967) · Medical Entomology and Zoology · Cited by 3,557
Rae, T. D., Schmidt, P. J., Pufahl, R. A., Culotta, V. C., & V. O'Halloran, T. (1999) · Science · doi:10.1126/science.284.5415.805 · Cited by 1,629
Theranostics: Combining Imaging and Therapy
Kelkar, S. S., & Reineke, T. M. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200151q · Cited by 1,385
Gabriel, M., Decristoforo, C., Kendler, D., Dobrozemsky, G., Heute, D., Uprimny, C., Kovacs, P., Von Guggenberg, E., Bale, R., & Virgolini, I. J. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.035667 · Cited by 1,010
Wadas, T. J., Wong, E. H., Weisman, G. R., & Anderson, C. J. (2010) · Chemical Reviews · doi:10.1021/cr900325h · Cited by 924
Smith, R. M., & Martell, A. E. (1989) · Springer eBooks · doi:10.1007/978-1-4615-6764-6 · Cited by 691
Potential Technetium Small Molecule Radiopharmaceuticals
Jurisson, S. S., & Lydon, J. D. (1999) · Chemical Reviews · doi:10.1021/cr980435t · Cited by 592
Hofmann, M., Maecke, H., Börner, A., Weckesser, E., Schöffski, P., Oei, M., Schumacher, J., Henze, M., Heppeler, A., Meyer, G., et al. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100639 · Cited by 544
Cited by
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
Robertson, A. K. H., Ramogida, C. F., Schaffer, P., & Radchenko, V. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180416161908 · Cited by 202
Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications.
Nelson, B. J. B., Andersson, J. D., & Wuest, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010049 · Cited by 194
Bismuth-213 for targeted radionuclide therapy: from atom to bedside.
Ahenkorah, S., Cassells, I., Deroose, C. M., Cardinaels, T., Burgoyne, A. R., Bormans, G., Ooms, M., & Cleeren, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050599 · Cited by 120
“The presence of the cyclohexyl moiety of CHX-A”-DTPA provides the chelator with additional rigidity and imposes a significant degree of preorganization on the metal ion binding site, augmenting kinetic inertness, but impeding radiolabeling kinetics as compared with DTPA [3].”
BackgroundMethodInfluentialArtificial Intelligence and the Future of Diagnostic and Therapeutic Radiopharmaceutical Development
Ataeinia, B., & Heidari, P. (2021) · PET Clinics · doi:10.1016/j.cpet.2021.06.008 · Cited by 31
Metadata
- Authors
- Price, E. W., & Orvig, C.
- Venue
- Chem. Soc. Rev.
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2014
- Volume
- 43
- Issue
- 1
- Pages
- 260-290
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W1966335626
- Cited by
- 1,018
- References
- 166
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Matching chelators to radiometals for radiopharmaceuticals. https://app.cochat.ai/papers/10.1039/c3cs60304k
- The paper
- Price, E. W., & Orvig, C. (2014). Matching chelators to radiometals for radiopharmaceuticals. Chem. Soc. Rev. https://doi.org/10.1039/c3cs60304k
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
